Assessing advantages of sequential boron neutron capture therapy (BNCT) in an oral cancer model with normalized blood vessels

作者：Molinari Ana J; Thorp Silvia I; Portu Agustina M; Saint Martin Gisela; Pozzi Emiliano C C; Heber Elisa M; Bortolussi Silva; Itoiz Maria E; Aromando Romina F; Monti Hughes Andrea; Garabalino Marcela A; Altieri Saverio; Trivillin Veronica A; Schwint Amanda E^*

来源：Acta Oncologica, 2015, 54(1): 99-106.

DOI：10.3109/0284186X.2014.925140

Background. We previously demonstrated the therapeutic success of sequential boron neutron capture therapy (Seq-BNCT) in the hamster cheek pouch oral cancer model. It consists of BPA-BNCT followed by GB-10-BNCT 24 or 48 hours later. Additionally, we proved that tumor blood vessel normalization with thalidomide prior to BPA-BNCT improves tumor control. The aim of the present study was to evaluate the therapeutic efficacy and explore potential boron microdistribution changes in Seq-BNCT preceded by tumor blood vessel normalization.
Material and Methods. Tumor bearing animals were treated with thalidomide for tumor blood vessel normalization, followed by Seq-BNCT (Th + Seq-BNCT) or Seq-Beam Only (Th + Seq-BO) in the window of normalization. Boron microdistribution was assessed by neutron autoradiography.
Results. Th + Seq-BNCT induced overall tumor response of 100%, with 87 (4)% complete tumor response. No cases of severe mucositis in dose-limiting precancerous tissue were observed. Differences in boron homogeneity between tumors pre-treated and not pre-treated with thalidomide were observed.
Conclusion. Th + Seq-BNCT achieved, for the first time, response in all treated tumors. Increased homogeneity in tumor boron microdistribution is associated to an improvement in tumor control.

• 出版日期2015-1